Prophase Labs Inc: (NASD: PRPH)
$1.58
0.01 (0.86%)
Volume 300
May 17 10:37 AM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 1.58 - 1.58 |
| 52wk Low - High | 0.98 - 2.25 |
| Previous Close | 1.57 |
| Avg. Volume | 7,700 |
| Industry | MED-DRUGS |
| Market Cap | 23.49 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.04 |
| PE (Forward) | 0.00 |
| Current Year Est. | 0.00 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
No Zacks Recommendation |
Zacks Industry Rank
|
88 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | NA |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | 08-12-2013 |
| EPS Last Year | -0.08 |
| Expected Earnings Growth | NA |
Company Description
ProPhase Labs, Inc., formerly known as The Quigley Corporation, is a manufacturer, marketer and distributor of a diversified range of homeopathic and health products that are offered to the general public. The Company's mission is to develop and market natural health care pharmaceuticals and nutriceuticals that offer pioneering new options to improve patient treatment results. Its consumer health products, marketed through ProPhase Labs and certain subsidiaries, include the original COLD-EEZE?, a zinc gluconate glycine product. COLD-EEZE? family of lozenges and sugar free tablets reduce the severity and duration of the common cold. Its customers include wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. ProPhase Labs is also engaged in the research and development of potential natural base health products along with supplements and cosmeceuticals for human and veterinary use. The Company is headquartered in Doylestown, Pennsylvania.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| JAZZ PHARMACEUT | JAZZ | 58.36 | |
|
| SALIX PHARM-LTD | SLXP | 59.28 | |
|
| SANTARUS INC | SNTS | 21.91 | |
|
| USANA HLTH SCI | USNA | 65.46 | |
|
| BIOCRYST PHARMA | BCRX | 1.71 | |
|
| CATALYST PHARMA | CPRX | 0.83 | |
|
| CELL THERAPEUT | CTIC | 1.16 | |
|
| CUBIST PHARM | CBST | 49.51 | |
|
| ELAN CP PLC ADR | ELN | 11.67 | |
|
| INFINITY PHARMA | INFI | 24.91 | |
|
Sector:Medical>> Industry:MED-DRUGS
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | -0.08 |
| Sales | 22 |
| Net Income | -0 |
| Price/Earnings | NA |
| Price/Book | 2.05 |
| Price/Cash Flow | NA |
| Price/Sales | 0.98 |
News
Stocks Hitting 52-Week Highs - Benzinga
Feb 26, 2013
Benzinga`s M&A Chatter for Monday October 29, 2012 - Benzinga
Oct 29, 2012
Benzinga`s Microcap Movers for Wednesday October 10, 2012 - Benzinga
Oct 10, 2012
Benzinga`s M&A Chatter for Tuesday October 9, 2012 - Benzinga
Oct 9, 2012
Matrixx Initiatives Files Presentation with SEC Regarding Offer To Acquire ProPhase Labs - Benzinga
Oct 9, 2012
Matrixx Initiatives Increases Offer For ProPhase Labs to $1.60/Share in Cash - Benzinga
Oct 9, 2012
Morning Market Movers - Benzinga
Oct 4, 2012
ProPhase Labs Rejects Non-Binding $1.40 Proposal - Benzinga
Sep 17, 2012
Broker Recommendations
| Current ABR | NA |
| ABR (Last Week) | NA |
| # of recs in ABR | NA |
| Average Target Price | NA |
| Industry Rank by ABR | 88 out of 265 |
| Rank in Industry | NA |
